Business
MEDITE Cancer Diagnostics Reports 2017 Second Quarter and First Six Month Financial Results
MEDITE Cancer Diagnostics Reports 2017 Second Quarter and First Six Month Financial Results.
About this update from Medite Cancer Diagnostics Inc
[{"type":"text","content":"\n \n \n MEDITE Cancer Diagnostics Reports 2017 Second Quarter and First Six Month Financial Results\n \n \nMEDITE Cancer Diagnostics Reports 2017 Second Quarter and First Six Month Financial Results\n\nStrengthening of manufacturing controls and comprehensive corporate review has positioned MEDITE for new product launches and sustainable growth\n\n \n ORLANDO, FL--(Marketwired - Aug 14, 2017) - MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT) (the \"Company\"), specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions, today announced its 2017 second quarter and first six month financial results.\n David Patterson, CEO of MEDITE, stated, \"During the second quarter of 2017, our team focused on taking the necessary steps to improve our manufacturing process and efficiencies. We undertook a purposeful slowdown in production in order to fully address the various issues and required changes. This in-depth manufacturing analysis was part of a full review of the Company's manufacturing, marketing and R&D infrastructure. We took tangible steps towards bolstering each segment to ensure that they support our long-term growth strategy and help build sustainable shareholder value. By the end of June, we saw a recovery in sales, which supports our confidence in end-user demand for our products, and positions MEDITE for a strong second half of the year, which are typically the Company's strongest quarters.\" \n Operational Highlights\n MEDITE Plans Worldwide Launch of the C1 SureCyte™ Stain at the 29th European Congress of Pathology in Amsterdam: \n \n \n Scheduled the global launch of a \"first of its kind\" innovative stain that is self-mounting and allows physicians to utilize high quality digital imaging to visualize and quantify cellular structure in a time saving, cost containment method that has not been available to the market previously.\n \nProduct will be available for order at the 29th European Congress of Pathology in Amsterdam, which will take place September 2-5, 2017 initially focused on the U.S., Europe and China markets.\n \nInitial revenues are expected in the fourth quarter of 2017.\n \n \n \n \n MEDITE Restructures Manufacturing and Production: \n \n \n Restructured manufacturi...